Member Info for McMakhlas

That’ll be the AVACOTIT....

Tourism - 330M jobs and 7% of world exports...

https://www.economist.com/leaders/2020/05/28/how-tourism-will-survive-the-pandemic?utm_campaign=the-economist-today&utm_medium=newsletter&utm_source=salesforce-marketing-cloud&utm_term=2020-05-29&utm_content=article-link-6

So PL75, how seriously AVAGOTIT?

Good video thanks - explains it very well...

GLA

11 May 2020 RNS

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that today it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners.

"I am delighted that the COVID-19 antigen test development programme continues ahead of schedule and we are today shipping the Affimer reagents to our partners to begin test development.

It is a major accomplishment to have generated Affimer reagents that can work in pairs as well as singly, as this opens up the potential for detecting the detached spike proteins as well as the intact virus particles, which means that we should have the best possible COVID-19 antigen test.

Another important step has been taken in delivering these tests to end users. I look forward very much to updating the market on further progress over the NEXT FEW WEEKS."

GLA

https://twitter.com/philorford/status/1263127629613408259?s=21

Not my opinion, but the World Health Organisations....

https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19

Sanofi now have $6.1Bn to spend on acquisitions....

https://www.google.ae/amp/s/amp.ft.com/content/7557514b-187f-4f61-8c11-b7a623f64eda

Would that be the same thermal scanners that won’t pick up asymptomatic people....as I posted earlier I think they may be trying to do a deal for rapid antigen tests if the news here is good...

$665k Fever Detection deal...

https://m.londonstockexchange.com/exchange/mobile/news/detail/14552307.html

No. 5: I am looking forward to working with the Medusa19 team on commercialising the COVID-19 rapid test and other consumer diagnostic tests that Avacta develops in the future, in line with the Group's Affimer diagnostics strategy."

No.4 : The Group is very actively exploring further commercial opportunities to develop them [Affimers] with partners into diagnostic tests.

90,000 PCR tests in UK produce ‘void’ results....

From the Spectator:

However, there is a third category of result: void tests. These are tests that proved inconclusive, either because the sample wasn’t taken correctly or because of some other issue involving the lab. Essentially, the test failed. There have been reports in recent weeks that suggest such failures, but now Coffee House can reveal that at least 91,000 swab tests have come back as void.

Currently, over 8 per cent of people who were tested in ‘pillar two’ have been told that their test result is ‘unclear’. Pillar two is the strand of the government’s testing strategy that deals with at-home tests and those carried out at drive-through centres. This pillar is designed for certain key workers and those who have been randomly selected for testing.

The real figure could be even higher than 91,000. The department was unable at the time of writing to give an exact number of voided ‘pillar one’ tests – those carried out on sick patients and critical health workers which are processed in existing NHS labs. However, they suggested that there was a presumed base rate of around 3 per cent, which would suggest at least 30,000 more void tests.

Quidel info as below, so this has to be at least the baseline for AVACTA - that would be my assessment of a successful outcome and would obviously be sufficient to get the FDA and CE approvals...

The assay demonstrated acceptable clinical sensitivity (80%) when compared to an EUA molecular device. The assay demonstrated excellent clinical specificity (100%). There was no demonstrable cross-reactivity with seventy-nine (79) specimens containing seasonal CoVs detected by the BioFire® FilmArray® Respiratory Panel (20-229E, 19-HKU1, 20-NL63, 20-OC43).

And in the words of the man himself....

the key technical risk is overcome and we should be confident moving forward from this point....

GLA

Love this paragraph in the article...

It comes after Superdrug yesterday became the first high street shop to sell a home test for Covid-19, with kits selling out within hours of being added to their website.

https://www.google.ae/amp/s/en.brinkwire.com/amp/news/almost-1-in-5-in-london-have-coronavirus-antibodies-as-tests-will-be-rolled-out-next-week-matt-han****-confirms/

Well AZN are $1.2Bn better off as of yesterday....

Listen again to the following....

https://webcasting.brrmedia.co.uk/broadcast/5e985bc231da814c9fc6a477/5eb26b0a8258e57601000341

53 mins in - the key technical risk is overcome and we should be confident moving forward from this point....

https://www.ii.co.uk/analysis-commentary/ii-data-reveals-more-bullish-buysell-ratios-jisa-accounts-ii511760

It is only exclusive for consumer distribution (ie online shopping etc), non- exclusive for business orders....Anyone would surely think this is clever marketing by establishing a global supplier to the retail opportunities whilst retaining rights over distribution for larger commercial orders...

The Group has agreed an exclusive distribution agreement with Medusa19 for the supply of the COVID-19 rapid test direct to consumers globally, subject to the necessary regulatory approvals. Medusa19 will also have non-exclusive rights to supply the tests to businesses for workforce testing. The distribution agreement includes a profit-sharing arrangement.

Great find Steelwatch - sounds like us, here’s hoping that it is!! Good news very soon possibly....GLA